EuroPCR is one of the largest, international courses in cardiovascular medicine. REVA presented positive 2-year data from the FANTOM II trial of the Fantom bioresorbable scaffold in 240 patients. Highlights from the presentations:
- Low 5.0% rate of Major Adverse Cardiac Events (“MACE”)
- A single very late scaffold thrombosis event for a rate of 0.4%
- Sustained vessel lumen patency without evidence of chronic scaffold recoil.
See below for links to the data presentations.
Stay up-to-date with the latest news and information about Fantom and Fantom Encore.
|Wednesday, 23 May 2018|
|12:15 to 13:15
|FANTOM: the new vision of BRS performance
Chairpersons: Ulf Landmesser, Gregg W. Stone
Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds <view presentation>
New 24-month data from the FANTOM II clinical trial and initial results from Fantom BRS expansion trials <view presentation>
Insights from the FANTOM II serial OCT sub-study <view presentation>
Fantom BRS case reviews and introduction to the REVA Technique <view presentation>